Board summary
Key figures
37,775
Registered population
63.9% aged 18–64
13.4%
Aged 65+
ICB 19.9% · England 17.9%
27.6%
Ethnic minority (non-White)
13.1% Asian · England 9.6%
32.6%
In IMD quintile 1
ICB 17.1% · England 21.0%
~10,710
Core20 residents (est.)
Resident basis; registered basis ~11,521 · see page 3
5,022
Hypertension register
+1.56% in 3 yrs · England +5.60%
346
SMI register
37.5% of Gravesham's
500
COPD register
Reviews +10.76% in 3 yrs
Forecast to 2030
6,076
Hypertension patients, 2030
+1,054 on today
85.0%
QRISK ≥20% on statins, 2030
+9.32pp over 3 yrs
2.8%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual reviews trail comparators and declined.
Annual asthma reviews fell 5.4% over 2023 to 2025 to 53.9% (England 65.7%), leaving about 720 of 1,565 registered patients without a review.
Working-age hypertension and diabetes control lag England.
Blood pressure control under age 80 is 59.2% (England 67.8%, vs 79.1% aged 80+), while non-frail diabetes HbA1c control is 47.3% (England 57.4%).
Rapid three-year growth in lipid-lowering therapy.
Patients with QRISK ≥ 20% on lipid-lowering therapy rose +18.0% over 2023 to 2025 to 61.8% (England +6.2%), at £1.30 per item (England £1.86).
Population, age and ethnicity
A younger list and 27.6% ethnic diversity may shape local primary care demand
Gravesend Central PCN has 37,775 registered patients, though practice lists sum to 35,752. The list is younger than benchmarks: 22.6% are aged 0-17 (Gravesham 22.1%, NHS Kent and Medway ICB 20.7%, England 19.6%) and 13.4% are aged 65+ (Gravesham 16.2%, ICB 19.9%, England 17.9%). Projected growth to 2030 is 7.2% (Gravesham 4.1%, ICB 6.0%, England 2.3%), under unverified methodology.
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Gravesham local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Gravesham LA) | 2,011 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 78.8% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 47.3% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Gravesham LA) | 1,055 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Gravesham LA) | 13.1 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 32.6% PCN-wide, peaking at 38.3% at Gravesend Medical Centre
Gravesend Central PCN has an average IMD decile of 3.6 (England 5.5). Registered Core20 patients reach 32.6%, above Gravesham (25.0%), NHS Kent and Medway ICB (17.1%) and England (21.0%). The weighted practice share is 32.2%, differing by 0.43 percentage points from the PCN figure. Practice share spans 14.3 pp: Gravesend Medical Centre is at 38.3% (6,393 estimated patients), Pelham Medical Practice at 27.6% (4,227 estimated patients), and Rochester Road Surgery at 24.0% (901 estimated patients).
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
346
SMI register
0.97% recorded prevalence
254
Learning disability register
0.71% recorded prevalence
15
Care homes, 591 beds
In the PCN catchment
9.3%
Provide unpaid care
Gravesham, Census 2021
The PCN records 346 patients on the severe mental illness register (1.0%, England 1.0%) and 254 with learning disabilities (0.7%, England 0.6%). There are 15 care homes with 591 beds in the PCN catchment, which do not establish patient residence. For Gravesham, the autumn 2025 snapshot recorded 8 rough sleepers, and Census modelling yields an unpaid carer ceiling estimate of 3,513.
Severe mental illness: physical health checks
On the 346-patient SMI register, blood pressure checks reached 75.9% (England 83.4%) and BMI recording was 79.3% (England 82.1%), while alcohol recording for psychosis was 73.5% (England 81.8%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,022
Hypertension register
+1.56%
Register growth, 3 yrs
Gravesham +4.52% · England +5.60%
+3.41pp
BP control, under 80
≤140/90 · +7.06pp aged 80+
+1,054
More patients by 2030
Forecast 6,076 (14.49%)
Hypertension case-finding and control
The hypertension register records 5,022 patients (14.1% prevalence), matching Gravesham (14.1%) but below NHS Kent and Medway ICB (16.2%) and England (15.2%). While blood pressure control aged 80+ reaches 79.1% (England 81.2%), control under age 80 is 59.2%, trailing Gravesham (62.9%), the ICB (64.6%) and England (67.8%), dropping to 46.6% at Rochester Road Surgery. Recent blood pressure recording is 83.1% (England 90.0%). Observation periods were not supplied, and the register implies a 35,693 base rather than the 37,775 list. Working-age blood pressure control lags national benchmarks across the PCN, with Rochester Road Surgery recording the lowest control rate.
Lipids and statins
Patients with QRISK ≥ 20% on lipid-lowering therapy rose +18.0% over 2023 to 2025 to 61.8%, above Gravesham (58.9%) and NHS Kent and Medway ICB (61.4%) but below England (63.6%).
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 59,920 | £1.30 | £1.90 | £1.86 | £77,896 |
| Cardiovascular (all), 2025 | 86,680 | £3.27 | £3.57 | £3.33 | £283,444 |
In 2026, the PCN prescribed 59,920 lipid-regulating items at £1.30 per item, below Gravesham (£1.61), England (£1.86) and NHS Kent and Medway ICB (£1.90), spending £33,555 less than at England's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−5.38%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.09%
Asthma prevalence, PCN 3-yr % change
Asthma annual reviews fell 5.4% over 2023 to 2025 (England +4.4%) to 53.9% (England 65.7%), leaving about 720 of 1,565 registered patients unreviewed. Practice review rates span from 45.6% at Pelham Medical Practice to 69.9% at Rochester Road Surgery. Conversely, COPD reviews rose 10.8% over 2023 to 2025 (England +2.8%) to 70.0% (England 76.4%, register 500). Second-hand smoke status was recorded for 69.8% of asthma patients aged 6-19 (England 78.8%).
Cancer register and children's immunisation
Cancer register prevalence is 2.5% (875 patients), below England (3.8%). In Q1 2025/26, childhood immunisation trailed the 95.0% target: 6-in-1 at 24 months was 88.8%, MMR dose 1 at 24 months was 82.2%, age-5 MMR dose 2 was 81.6% (below target by 13.4 pp), and pre-school 4-in-1 booster coverage was 78.9% (below target by 16.1 pp).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
In 2022, NHS Kent and Medway ICB diagnosed 55.6% of staged cancers at stage 1 or 2 (England 55.3%), below the 75.0% national ambition by 2028; staging was known for 63.6% of registered cancers, requiring 1,627 extra early-stage cases a year to reach 75%. System-level staging does not measure PCN performance, but local preventive uptake is low: cervical screening coverage is 58.2% (England 66.8%), with Rochester Road Surgery at 53.6%, and breast screening is 57.2% (England 69.9%). Lower screening reach could reflect unverified engagement barriers that a recall audit would test, potentially delaying early identification.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In provisional Jul 2026 data, Dartford and Gravesham NHS Trust met the 62-day cancer referral to treatment standard for 63.6% of pathways (85.0% standard), below Medway NHS Foundation Trust (81.6%), NHS Kent and Medway Integrated Care Board (75.9%), and England (71.2%). However, it met the 28-day faster diagnosis standard at 78.1% (standard 75.0%) and the 31-day combined treatment standard at 97.5% (standard 96.0%). For all diagnostic tests, 8.4% of patients waited 6+ weeks (England 23.1%). Prolonged 62-day waits at the local acute provider could delay treatment initiation.
| Pathways within standard (%) | Dartford and Gravesham | Medway | Kent and Medway ICB | England |
|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 78.14 | 77.77 | 76.78 | 79.32 |
| 31-day treatment (96%) | 97.48 | 99.62 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 63.59 | 81.64 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Dartford and Gravesham | Kent Health | Medway | England |
|---|---|---|---|---|
| MRI | 0.36 | — | 0.68 | 21.40 |
| CT | 2.08 | — | 0.00 | 9.92 |
| Echocardiography | 3.90 | — | 36.62 | 28.48 |
| Colonoscopy | 0.40 | — | 1.88 | 30.83 |
| Gastroscopy | 0.00 | — | 3.32 | 29.02 |
| All 15 DM01 tests | 8.37 | 27.49 | 14.20 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). In provisional Jun 2026 data, Kent residents received 210,170 community care contacts across 265,905 care activities covering 60,605 patients, with 65.8% of contacts involving adults aged 65+. Regionally, NHS Kent and Medway Integrated Care Board recorded 254,055 contacts. These experimental provider counts describe wider-system activity and are not PCN-specific.
Practice variation and patient experience
Good practice experience spans 19.9 pp while vaccination achievement varies by 41.7 pp
In 2025/26, QOF overall achievement ranged from 71.5% at Rochester Road Surgery to 94.5% at Pelham Medical Practice (England 92.5%). Across practices, vaccination achievement spanned 41.7 pp: Gravesend Medical Centre achieved 15.6% against an England level of 55.2%, while Pelham Medical Practice reached 57.3%.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Rochester Road | 69 | 24.0 | 61.9% | 73.0% | 81.8% |
| Gravesend | 87 | 38.3 | 55.6% | 75.6% | 66.0% |
| Pelham Medical | 126 | 27.6 | 45.9% | 74.9% | 61.9% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Eleven tracked measures lagged England while dementia fell 5.4% and stroke fell 1.9%
Over 2023 to 2025, 11 of 25 tracked measures lagged England. Slower relative three-year trends were led by dementia QOF prevalence, which fell 5.4% (England +6.0%), asthma annual reviews, which fell 5.4% (England +4.4%), and stroke prevalence, which fell 1.9% (England +2.3%). Hypertension register growth also lagged at +1.6% (England +5.6%). Conversely, relative gains occurred in QRISK ≥ 20% lipid therapy at +18.0% (England +6.2%) and COPD reviews at +10.8% (England +2.8%), alongside SMI BMI checks increasing +17.1 pp (England +5.1 pp).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Dementia register
Asthma reviews
Stroke register
Hypertension register
Cancer register
BMI record (SMI)
QRISK statin treatment
COPD reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Gravesham | Asset | PCN | Gravesham |
|---|---|---|---|---|---|
| Care homes (catchment) | 15 (591 beds) | n/a | Schools (catchment) | 69 | n/a |
| Children's centres | 5 | 5 | Places of worship | 31 | 46 |
| Libraries | 5 | 8 | Food banks (VCS) | 1 | 1 |
| Day centres (VCS) | 9 | 13 | Children and young people (VCS) | n/a | 1 |
| Carers support groups (VCS) | n/a | 2 | Primary schools (LA maintained) | 12 | 16 |
| Primary academies | 13 | 16 | Special schools | 3 | 4 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Asthma annual review coverage is 53.9% (Gravesham 58.5%, NHS Kent and Medway ICB 60.4%, England 65.7%), leaving an estimated 722 (about 720) of 1,565 registered patients unreviewed. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Working-age hypertension control and recall
On the 5,022 hypertension register, blood pressure control under age 80 is 59.2% (Gravesham 62.9%, NHS Kent and Medway ICB 64.6%, England 67.8%), below England by 8.7 pp; patient count is not sized. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Combined SMI physical health checks
On the 346-patient SMI register, annual BP checks are 75.9% (Gravesham 77.7%, NHS Kent and Medway ICB 79.7%, England 83.4%), below England by 7.5 pp; patient count is not sized. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Demographic outreach and list reconciliation (p2) | Registered population | Neighbourhood health framework | PCN |
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall audit (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Working-age hypertension recall audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school immunisation recall audit (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephony and access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN & Practice |
| Option 2 · Working-age hypertension control and recall (p12) | Hypertension register · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) · Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 3 · Combined SMI physical health checks (p12) | Severe mental illness register · SMI register with a BP check in the last 12 months · SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
